Celcuity (NASDAQ: CELC) is one of 23 publicly-traded companies in the “Medical laboratories” industry, but how does it compare to its peers? We will compare Celcuity to similar companies based on the strength of its dividends, institutional ownership, risk, profitability, analyst recommendations, valuation and earnings.
Earnings & Valuation
This table compares Celcuity and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Celcuity Competitors||$1.13 billion||$90.54 million||463.41|
This table compares Celcuity and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
14.4% of Celcuity shares are owned by institutional investors. Comparatively, 52.0% of shares of all “Medical laboratories” companies are owned by institutional investors. 43.5% of Celcuity shares are owned by company insiders. Comparatively, 17.4% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk & Volatility
Celcuity has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, Celcuity’s peers have a beta of 1.37, suggesting that their average share price is 37% more volatile than the S&P 500.
This is a breakdown of recent ratings and target prices for Celcuity and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Celcuity currently has a consensus target price of $35.50, indicating a potential upside of 31.97%. As a group, “Medical laboratories” companies have a potential upside of 4.05%. Given Celcuity’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Celcuity is more favorable than its peers.
Celcuity beats its peers on 7 of the 13 factors compared.
Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer. It is also developing CELx tests to diagnose 14 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.